StockpollyBeta
Get App
Delisting riskPopularity #4,119
AEON · AMEX · Biotechnology

AEON Biopharma (AEON)

Develops a therapeutic Botox biosimilar candidate for broad-label use.

$0.2678
vs last close+0.01 (+2.21%)

In millions of USD, except per-share figures

In millionsQ4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue00000000000
Gross profit00000000000
3574−15342042666
Research & development76413111223
Selling, general & administrative55333332443
Other expenses2364−1610−3−300000
Operating income−35−74153−4−20−4−2−6−6−6
8−4411−2410−2−2−32−65
Other non-operating income−23−6416123300060
Income before tax−26−118164−629−7−5−37−12−1
Net income from continuing operations−26−118164−629−7−5−37−12−1
Net income−26−118164−629−7−5−37−12−1
EPS, basic−$50.82−$228.00$304.20−$11.24$3.76$2.28−$0.60−$0.39−$3.07−$0.29−$0.02
EPS, diluted−$50.82−$228.00$304.20−$11.24$3.75$2.28−$0.60−$0.39−$3.07−$0.29−$0.02
Weighted average shares, basic1111141112124151
Weighted average shares, diluted1111141112124151
EBITDA−12−10−8−6−6−4−4−3−5−12−6
Depreciation & amortization00000000000
EBIT−12−10−8−6−6−4−4−3−6−12−6